11 Mar 2015 Posted in News Release By Press Office
Commenting on the appointments ABPI Executive Director Commercial UK Alison Clough said:
“The UK lags behind comparable countries when it comes to patients seeing the benefits of new medicines. Improving patient access to new medicines in the UK would not only save and enhance patients’ lives but also unlock the value of the life sciences sector, making the UK a powerhouse for innovation.
"We hope that this announcement will represent an important step forward in improving access to modern medicines for the right patient, at the right time. By joining up across development, regulation, pricing, value assessment and medicines usage this Review has the potential to create a reformed health system fit for the 21st Century. In order to achieve this, it is essential that the Review considers NICE’s role and its alignment with NHS England, with changes made to the way NICE evaluates new medicines.
“We look forward to working in partnership with policymakers, the NHS, clinicians and patient representatives as part of this Review in order to help remove the barriers patients face in access to new medicines.”
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press Office
Telephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811